Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials
Zebo Huang1, Yinxia Wu, Xin Zhou
1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.
Abstract:
The ubiquitin-proteasome system is a major pathway for protein degradation, so that proteasome is now considered as an important target for drug discovery. Bortezomib, the first US FDA-approved proteasome inhibitor now used as a front-line treatment for multiple myeloma. To better understand the effects of bortezomib in cancer treatment, we carried out a review based on 32 published clinical trials to determine whether bortezomib will benefit patients with solid tumors. Information of complete response, partial response, stable disease and objective response rate was collected to assess clinical outcomes. A lack of therapeutic effects was observed when bortezomib was used as a single agent. Meanwhile, when bortezomib treatment was combined with other agents, bortezomib offered no statistically significant response versus these agents alone. High-quality studies are required to better understand the clinically effects of bortezomib and the development of a new generation of proteasome inhibitors is absolutely necessary.
Insights
Bortezomib, a proteasome inhibitor, showed limited benefit for solid tumors in a review of 32 clinical trials. Combination therapies did not significantly improve outcomes compared to single agents, highlighting the need for new treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The ubiquitin-proteasome system regulates protein degradation and is a key target for cancer drug discovery.
- Bortezomib is the first FDA-approved proteasome inhibitor, primarily used for multiple myeloma.
Purpose of the Study:
- To evaluate the efficacy of bortezomib in solid tumors through a comprehensive review of clinical trials.
- To determine if bortezomib offers therapeutic benefits as a single agent or in combination therapies for solid tumors.
Main Methods:
- Systematic review of 32 published clinical trials involving bortezomib treatment for solid tumors.
- Analysis of clinical outcomes including complete response, partial response, stable disease, and objective response rate.
Main Results:
- Bortezomib demonstrated a lack of significant therapeutic effects when used as a single agent in solid tumors.
- Combination therapies involving bortezomib did not yield statistically significant improvements in response rates compared to other agents alone.
Conclusions:
- Current evidence suggests limited clinical benefit of bortezomib for patients with solid tumors.
- Further high-quality studies are essential to clarify bortezomib's role, and the development of next-generation proteasome inhibitors is crucial.
Related Concept Videos
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...